Jump to section
To bring better drugs faster to the patients who can benefit most, through machine learning and data at scale.
28% employee growth in 12 months
The synthetic biology market is rapidly growing, projected to increase from $10.7B in 2021 to over $74.7B by 2031. This growth is fueled by advances in biotechnology and expanding applications in healthcare, agriculture, and energy.
With these rapid advancements, insitro is seizing the opportunity to lead the way. The company is transforming drug discovery by combining machine learning with high-throughput biology. By using AI, insitro aims to overcome the bottlenecks of traditional methods, driving down costs and enabling the development of more effective treatments.
To help it on its mission, insitro recently secured strategic agreements with Eli Lilly for metabolic disease treatments and it also expanded its leadership in AI/ML. With this, the company is surely set to accelerate drug development, promising a future of faster and more effective treatments for patients.
Freddie
Company Specialist at Welcome to the Jungle
Mar 2021
$400m
SERIES C
May 2020
$143m
SERIES B
This company has top investors
Daphne Koller
(Founder & CEO)Co-founder of engageli and previously Coursera. They also spent a year at CalicoLabs as the Chief Computing Ofificer and over 18 years at Stanford University as a Professor.
Data
Finance, Legal & Compliance